Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
Study Details
Study Description
Brief Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Early Phase 1 |
Detailed Description
This is a single arm , open-label study. This study is indicated for relapsed and/or refractory CD19+ B-cell Acute Lymphoblastic Leukemia . The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products.
- Main research objectives:
To evaluate the safety and efficacy of metabolically armed CD19 CAR-T Cells in the treatment of r/r B-ALL.
- Secondary research objectives:
-
To evaluate the pharmacokinetic (PK) and pharmacodynamics(PD) characteristics of metabolically armed CD19 CAR-T Cells after infusion.
-
To evaluate tumor remission after infusion of metabolically armed CD19 CAR-T Cells.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Administration of Metabolically Armed CD19 CAR-T cells Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0. |
Drug: Metabolically Armed CD19 CAR-T cells
Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- MTD [MTD will be determined based on DLTs observed during the first 28 days of study treatment]
Determine the Maximal Tolerable Dose(MTD)
- Objective response rate (ORR) [Within 3 months following infusion of Meta10- 19]
Measure Tumor response rate (including CR and PR)
Secondary Outcome Measures
- Pharmacokinetics [Up to 12 months after CAR-T treatment]
The number of CAR-T cells in peripheral blood was measured to evaluate the persistence of CAR-T cells
- Pharmacodynamics [Up to 28 days after infusion]
Peak level of cytokines in peripheral blood
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The patient or his/her guardian voluntarily signed the informed consent;
-
Adult Patients with relapsed and refractory B-cell Acute Lymphoblastic Leukemia.
Definition of relapsed or refractory B-ALL (meeting one of the following conditions):
-
2 or more relapses;
-
Bone marrow relapsed after allo-HSCT and prepared to infuse Meta10-19 more than 6 months after allo-HSCT ;
-
CR not achieved after standardized chemotherapy;
-
Philadelphia-chromosome-positive (Ph+) patients who are ineffective or intolerant to first- and second-generation tyrosine kinase inhibitor (TKI) treatments, or who have contraindications to tyrosine kinase inhibitors;
-
The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is ≥ 5%
-
CD19 expression was positive by biopsy or flow cytometry (accept the results of this peripheral blood mononuclear cells collection or previous Class A tertiary hospital before this peripheral blood collection);
-
Expected survival time greater than 12 weeks
-
The baseline ECOG score was 0 or 1;
-
Organ function:
-
Kidney function:
Serum creatinine ≤1.5 times ULN, or; The glomerular filtration rate (eGFR) estimated by MDRD formula was ≥60m/min/1.73m2;[eGFR=186×(age)-0.203×SCr-1.154(mg/dl),for females, the result was ×0.742];
-
Liver function: ALT≤5 times ULN, and; Patients with total bilirubin ≤2.0mg/dl, except those with Gilbert-Meulengracht syndrome. Patients with Gilbert-.Meulengracht syndrome with total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN were included.
-
Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) ≥91% in indoor air environment.
-
Hemodynamic stability was determined by echocardiography or multichannel radionuclide angiography (MUGA) and LVEF ≥45%;
-
Patients using the following drugs must meet the following conditions:
-
Steroid: Therapeutic doses of steroids must be discontinued 2 weeks prior to Meta10-19 infusion. However, physiological replacement doses of steroids are permitted, hydrocortisone or its equivalent < 6-12mg/mm2/ day;
-
Immunosuppressive agent: Any immunosuppressive drug must be stopped ≥4 weeks before the informed consent is signed;
-
Anti-proliferative therapy other than preconditioning chemotherapy is discontinued within 2 weeks prior to Meta10-19 infusion;
-
Treatment for CNS disease must be stopped 1 week before Meta10-19 infusion (e.g., intrathecal methotrexate)
-
The patient has recovered from the toxicity of the previous treatment, that is, the CTCAE toxicity grade is less than 1 (The exception is specific toxicity of grade 2 or less, such as hair loss, which the researchers have determined is not recoverable in a short period of time) is suitable for pretreatment chemotherapy and CAR-T cell therapy;
-
Women of childbearing age and all male patients must consent to use an effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR-T cells in vivo.
Exclusion Criteria:
-
Patients with isolated extramedullary relapse;
-
Patients with confirmed diagnosis of Burkitt's lymphoma/ leukemia;
-
Patients who had received prophylaxis for CNS leukemia within 1 week prior to Meta10-19 infusion;
-
Patients with present or history of central nervous system diseases such as seizures disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement;
-
Patients with history of allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 6 months prior to Meta10-19 infusion;
-
Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion ;
-
Patients who participated in other clinical trials within 30 days prior to enrollment;
-
Patients with active hepatitis B (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 1000 copies/ml) or hepatitis C (HCV RNA positive);
-
Patients with HIV antibody positive or treponema pallidum antibody positive;
-
Patients with uncontrolled acute life-threatening bacterial, viral or fungal infections (e.g. positive blood cultures ≤72 hours before Meta10-19 infusion)
-
Patients with unstable angina pectoris and/or myocardial infarction within 6 months prior to enrollment;
-
Patients with history of other malignancies, but the following conditions can be enrollment:
-
Adequately treated basal or squamous cell carcinoma (requiring adequate wound healing before signing informed consent);
-
Carcinoma in situ (DCIS) of cervical or breast cancer, which has been treated therapeutically, has shown no signs of recurrence for at least 3 years prior to the signing of the informed consent;
-
The primary malignancy has been completely resected and in complete remission for ≥5 years。
-
Women who are pregnant or breastfeeding (pregnancy tests for women of childbearing age are positive);
-
Patients with active neuroautoimmune or inflammatory conditions (e.g. Guillian-Barre syndrome, amyotrophic lateral sclerosis);
-
Other conditions that the investigator considered should not be enrolled in this clinical study, such as poor compliance.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Anhui Provincial Hospital | Hefei | Anhui | China |
Sponsors and Collaborators
- Anhui Provincial Hospital
- Leman Biotech Co., Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Meta10-19-002